hexamethylene bisacetamide has been researched along with Brain Neoplasms in 4 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The modulation effects of hexamethylene bisacetamide (HMBA), a differentiation-inducing agent, on growth and differentiation of cells from human malignant glioma cell line SHG-44 were studied." | 7.69 | Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. ( Du, ZW; Huang, Q; Li, XN, 1996) |
| "Hexamethylene bisacetamide (HMBA)-induced growth inhibition and differentiation of the rat C6 glioma cell line were found to be accompanied by down-regulation of the constitutively expressed fra-1 gene." | 3.72 | Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells. ( Shaikh, SA; Shirsat, NV, 2003) |
| "The modulation effects of hexamethylene bisacetamide (HMBA), a differentiation-inducing agent, on growth and differentiation of cells from human malignant glioma cell line SHG-44 were studied." | 3.69 | Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. ( Du, ZW; Huang, Q; Li, XN, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funck-Brentano, E | 1 |
| Vizlin-Hodzic, D | 1 |
| Nilsson, JA | 1 |
| Nilsson, LM | 1 |
| Shirsat, NV | 2 |
| Shaikh, SA | 1 |
| Li, XN | 1 |
| Du, ZW | 1 |
| Huang, Q | 1 |
| Kayal, JJ | 1 |
| Shaikh, S | 1 |
| Mehta, A | 1 |
4 other studies available for hexamethylene bisacetamide and Brain Neoplasms
| Article | Year |
|---|---|
BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma.
Topics: Acetamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2021 |
Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Astrocytoma; Brain Neoplasms; Bucladesine; Ce | 2003 |
Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells.
Topics: Acetamides; Adult; Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line; Dose-Res | 1996 |
Growth inhibition and differentiation of C6 glioma cells on treatment with hmba.
Topics: Acetamides; Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Division; | 2001 |